Abstract
Purpose :
NICE approved use of Faricimab (Vabysmo) for treatment of nAMD and DMO in the NHS in June 2022. This paper describes real life clinical experience of intravitreal Faricimab (Vabysmo) in the management of patients with neovascular macular degeneration (nAMD) and diabetic macular oedema (DMO), particularly looking at the changes on OCT imaging.
Methods :
All consecutive adult patients attending macula service who were treated with Faricimab (Vabysmo) for nAMD or DMO were included in the study. Both treatment naïve and previously treated eyes were eligible. Eyes with less than 3 months follow up data were excluded. All eyes had visual acuity assessment on ETDRS letter score using habitual correction and OCT assessment of macula at each visit. All eyes underwent intravitreal injections following standard operating process by nurse injectors following SMPC. OCT were analysed for central macular thickness (CMT), intra-retinal fluid (IRF), sub-retinal fluid (SRF) and sub RPE fluid (SRPEF).
Results :
57 eyes of 46 patients (28 F, 18 M) were included in the study. 37 eyes had nAMD (14 naïve, 23 previously treated) and 20 had DMO (9 naïve, 11 previously treated). With regards to the presence of fluid in nAMD patients at baseline, 18 eyes had IRF, 24 had SRF and 16 had SRPEF. At 3 months it was present in 9, 9 and 8 eyes, respectively (Figure 1). The mean CMT at baseline was 302 microns with a mean change at 3 months of -38 microns. Mean CMT in DMO patients was 460 microns at baseline with a mean change of -124 microns at 3 months (Figure 2). Treatment naïve eyes showed better response than previously treated eyes. No drug related adverse events were encountered with Faricimab (Vabysmo).
Conclusions :
Faricimab (Vabysmo) treated nAMD and DMO eyes showed improved macular anatomy after loading phase of injections. Early treatment response observed in real-life practice appears to be following the pattern of the pivotal studies on Faricimab. Further studies with longer follow up of patients treated with Faricimab (Vabysmo) are needed.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.